Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 17
---
holder.

For purposes of the Purchase
Agreement, “VWAP” shall mean the daily volume weighted average price of the Depositary Shares on Nasdaq as reported by Bloomberg
through its “AQR” function.

All such determinations shall
be appropriately adjusted for any sales of Depositary Shares through block transactions, any reorganization, non-cash dividend, stock
split, reverse share split, stock combination, recapitalization, Depositary Share-Ordinary Share ratio change or other similar transaction
during such period.

Commitment Fee, Commitment Shares and Other Fees

As consideration for its irrevocable
commitment to purchase our Depositary Shares under the Purchase Agreement, we have agreed to pay to the Selling Shareholder the Commitment
Fee as consideration for the Selling Shareholder entering into the Purchase Agreement. In the event that we fail to pay the Commitment
Fee when due, we shall have the right, at our discretion, to issue Depositary Shares representing the value of the Commitment Fee in aggregate,
valued at the closing sale price for the Depositary Shares on Nasdaq on the trading day immediately prior to the date of execution of
the Purchase Agreement, to release us of our liability to pay the Commitment Fee as a liquidated sum. To the extent Commitment Shares
are issued in lieu of paying the Commitment Fee, we intend to issue up to 612,500 Depositary Shares (equal to 1.75% of the Commitment
Amount) upfront, with the remainder paid upon each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as the case may be, until
such amount is paid in full.

We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of our company and in connection with the preparation, negotiation and execution of the Purchase Agreement.

Conditions Precedent to Commencement

Our right to commence delivering
Purchase Notices under the Purchase Agreement and the Selling Shareholder’s obligation to accept a Fixed Purchase Notice, VWAP Purchase
Notice or Additional VWAP Purchase Notice, are subject to the initial satisfaction, at the Commencement Date, of the conditions precedent
thereto set forth in the Purchase Agreement, which conditions include, among others, the following:

| · | the accuracy in all material